Table 2.

Ongoing trials of EGFR inhibitors in combination for advanced gastric/esophagogastric cancer.

Drug	Target	Evaluation of EGFR status	Status (Phase of trial)	Type of cancer	Results
ONGOING CLINICAL TRIALS WITH INHIBITORS THAT BLOCKS EGFR MEMBRANE ASSOCIATION
FOLFOX + FOLFIRI + FOLTAX + ABT-806 (anti-EGFR monocolonal antibody) (as part of PANGEA – IMBBP trial)	EGFR	EGFR amplification by NGS status required for the enrollment	NCT02213289	Esophagogastric adenocarcinoma	In progress
Intravenous GC-1118 (EGFR inhibitor) in combination with weekly paclitaxel	EGFR	EGFR amplification or strong (3+) EGFR immunostaining	NCT04077255	Esophagogastric adenocarcinoma	Not yet recruiting
FATE-NK100 in combination with cetuximab (EGFR inhibitor)	HER2, EGFR	EGFR+ and/or HER2+	NCT03319459	Esophagogastric adenocarcinoma	In process—recruiting
Varlititib (EGFR inhibitor) + mFOLFOX6	EGFR, HER2, HER4	IHC and FISH	NCT03130790	Gastric	Phase II/III

CR, complete response; CI, confidence interval; HR, hazard ratio; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; PR, partial response; RR, response rate; WT, wild type; ORR, objective response rate.